NovaBay Pharmaceuticals, Inc.

Good day and welcome to the Nova Bay Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Jody Kane. Please go ahead.

This is Jody Kane with LHA. Thank you for participating in today's call. Joining me from Nova Bay are Justin Hall, Chief Executive Officer and General Counsel, Andy Jones, Chief Financial Officer, and Dr. Audrey Keenan, the company's new chief product officer. I would like to remind listeners the comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any anticipated results. In particular, there is uncertainty about the future operations of Nova Bay's newly acquired subsidiary, Dermadoctor, and the duration of potential impact of the ongoing COVID-19 pandemic. This means that results could change at any time, and the contemplated impact of Nova Bay's recent acquisition and COVID-19 on Nova Bay's operations, its financial results, and its outlook is a best estimate based on the information available for today's discussion. For a list and description of risks and uncertainties, please review Nova Bay's filings with the Securities and Exchange Commission at sec.gov. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live podcast, November 11, 2021. Nova Bay undertakes no obligation to revise or update any statements to reflect events or circumstances except as required by law. And now I'd like to turn the call over to Justin Hall. Justin?

Thank you, Jody. Good afternoon, everyone, and thank you for joining us. I would like to welcome the entire Derma Doctor team and our new shareholders to today's call. The purpose of today's call is twofold. The first is to review NovaBay's third quarter performance. The second and more important purpose of the call is to talk about NovaBay's acquisition of Derma Doctor. Last Friday, I was in Kansas City with the Dermadoctor team when we closed on the transaction and officially became one company. This was just days after closing the $15 million private placement. We appreciate the strong reception we received for this financing in the investment community, which we see as an endorsement of the financials and strategy underlying the Dermadoctor acquisition. Now, more than ever, I'm extremely optimistic about NovaBay's future. Dermadoctor's new product development capabilities will put us on a growth trajectory previously unattainable as a one-product company. That said, we continue to see strong performance from our Avanova business. Avanova revenues year-to-date have increased 16% over the same period last year, with unit sales reaching an all-time high, as more people than ever are using Avanova today than ever before. Before discussing Dermadoctor and our new product pipeline, I'll turn the call over to Andy to review NovaBay's standalone financial performance from Q3, a period prior to the acquisition.